Intellia Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 526
- Market Cap
- $2.3B
- Website
- http://www.intelliatx.com
- Introduction
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
The transformative potential of biotechnology and AI in healthcare
Biotech and AI advances drive medicine's revolution with biologics surge, market growth, and precision medicine. Curative therapies, AI in drug discovery, and multiomics for early disease detection transform healthcare. CRISPR-based cures and AI-driven drug discovery reduce costs and time. Multiomics enhances cancer detection and treatment, improving survival rates and market expansion. ARK Genomic Revolution UCITS ETF offers exposure to these advancements.
Most HAE patients attack-free after NTLA-2002 treatment in trial
A Phase 2 clinical trial of gene-editing therapy NTLA-2002 showed that 50 mg doses led to an 80% reduction in swelling attacks over 16 weeks, with 8 out of 11 patients free from attacks. The 25 mg dose also showed positive results, with 40% of patients experiencing no attacks. Intellia Therapeutics, the developer, plans to advance the 50 mg dose to Phase 3 trials.
Seaport Therapeutics Secures $225M for New Kind of Depression Drug
Seaport Therapeutics raised $225 million to advance its lead drug candidate for depression, leveraging its Glyph technology platform. The company aims to advance its pipeline through clinical milestones and further develop its Glyph technology.
Sangamo Shares Surge on Shorter Pathway for Fabry Candidate
Sangamo Therapeutics' shares surged 69% after FDA alignment on an Accelerated Approval pathway for its Fabry disease gene therapy, isaralgagene civaparvovec (ST-920), using data from its Phase I/II STAAR trial. The company plans to submit a BLA in the second half of 2025, three years ahead of previous estimates.
Related Clinical Trials:
Intellia reports positive data from Phase II study of NTLA-2002 for HAE
Intellia Therapeutics reports positive Phase II results for NTLA-2002, a CRISPR-based gene editing therapy for hereditary angioedema (HAE), showing significant reduction in attack rates and well-tolerated doses, leading to selection of the 50mg dose for further Phase III evaluation.
CRISPR Gene Editor Cuts Hereditary Angioedema Attacks by 81% in Phase II Study
Intellia Therapeutics unveiled Phase II data for NTLA-2002, showing 80-81% reduction in monthly attacks with 25-50 mg doses in hereditary angioedema patients. Eight of 11 patients given 50 mg reached complete response. NTLA-2002 is well-tolerated, with no serious toxicities. Intellia plans to advance 50 mg dose to Phase III. Analysts are cautiously optimistic, though stock dropped 9% due to investor overreaction.
Promising Phase II Results and Market Potential Support Buy Rating for Intellia Therapeutics
Chardan Capital's Geulah Livshits maintains Buy rating on Intellia Therapeutics (NTLA) with a $88.00 price target, citing NTLA-2002's phase II trial data showing 77% reduction in HAE attacks. Despite high expectations not fully met, one-time dosing potential supports the rating. Livshits anticipates positive phase III results and differentiates NTLA-2002 from other treatments.
Gene-Editing Therapy Reduced Attacks in Hereditary Angioedema
A single dose of CRISPR-based NTLA-2002 reduced angioedema attacks by 75-77% in patients with hereditary angioedema, with 80% of patients in the 50 mg group experiencing complete response.
Related Clinical Trials:
Intellia Therapeutics stock plunges after phase 2 results from NTLA-2002 study
Intellia Therapeutics' stock dropped 20% after Phase 2 results of NTLA-2002 showed 75-81% reduction in HAE attacks, with 8/11 patients in the 50 mg dose group remaining attack-free for up to 8 months. Despite the therapy being well-tolerated, analysts lowered Intellia's price target to $18 due to concerns over in vivo gene editing risks and market competition.
© Copyright 2025. All Rights Reserved by MedPath